

Yves Fradet

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6023387/publications.pdf>

Version: 2024-02-01

38
papers

3,763
citations

430874

18
h-index

345221

36
g-index

39
all docs

39
docs citations

39
times ranked

6256
citing authors

#	ARTICLE	IF	CITATIONS
1	Follicle-stimulating hormone (FSH) levels prior to prostatectomy are not related to long-term oncologic or cardiovascular outcomes for men with prostate cancer. Asian Journal of Andrology, 2022, 24, 21.	1.6	2
2	Effects of omega-3 fatty acids supplementation on perioperative blood loss and complications after radical prostatectomy. Clinical Nutrition ESPEN, 2022, 47, 221-226.	1.2	2
3	Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials. Clinical Cancer Research, 2022, 28, 2050-2060.	7.0	21
4	Androgen receptor and immune cell PD-L1 expression in bladder tumors predicts disease recurrence and survival. World Journal of Urology, 2021, 39, 1549-1558.	2.2	9
5	Omega-3 Eicosapentaenoic Acid Reduces Prostate Tumor Vascularity. Molecular Cancer Research, 2021, 19, 516-527.	3.4	10
6	Dimensional reduction based on peak fitting of Raman micro spectroscopy data improves detection of prostate cancer in tissue specimens. Journal of Biomedical Optics, 2021, 26, .	2.6	4
7	Identification of intraductal carcinoma of the prostate on tissue specimens using Raman micro-spectroscopy: A diagnostic accuracy caseâ€“control study with multicohort validation. PLoS Medicine, 2020, 17, e1003281.	8.4	19
8	A prospective, multisite study analyzing the percentage of urological cases that can be completely managed by telemedicine. Canadian Urological Association Journal, 2020, 14, 319-321.	0.6	11
9	Does 5-alpha Reductase Inhibitor Use Improve The Efficacy of Intravesical Bacille Calmette-GuÃ©rin (BCG) for Non-muscle Invasive Bladder Cancer?. Bladder Cancer, 2020, 6, 63-69.	0.4	5
10	Assembling a network to promote translational bladder cancer research in Canada. Canadian Urological Association Journal, 2020, 14, E475-E481.	0.6	1
11	Omegaâ€“3 fatty acids decrease prostate cancer progression associated with an antiâ€“tumor immune response in eugonadal and castrated mice. Prostate, 2019, 79, 9-20.	2.3	28
12	Plasma extracellular vesicles as phenotypic biomarkers in prostate cancer patients. Prostate, 2019, 79, 1767-1776.	2.3	51
13	Receipt of 5-Alpha Reductase Inhibitors Before Radical Cystectomy: Do They Render High-Grade Bladder Tumors Less Aggressive?. Clinical Genitourinary Cancer, 2019, 17, e1122-e1128.	1.9	9
14	Retrospective study on the benefit of adjuvant radiotherapy in men with intraductal carcinoma of prostate. Radiation Oncology, 2019, 14, 60.	2.7	18
15	Increased Prostate Cancer Glucose Metabolism Detected by 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Localised Gleason 8â€“10 Prostate Cancers Identifies Very Highâ€“risk Patients for Early Recurrence and Resistance to Castration. European Urology Focus, 2019, 5, 998-1006.	3.1	25
16	Discordance between testosterone measurement methods in castrated prostate cancer patients. Endocrine Connections, 2019, 8, 132-140.	1.9	6
17	Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer. Journal of Clinical Oncology, 2018, 36, 1579-1587.	1.6	97
18	Canadian Urological Association guideline: Muscle-invasive bladder cancer. Canadian Urological Association Journal, 2018, 13, 230-238.	0.6	51

#	ARTICLE	IF	CITATIONS
19	Serum Sex Steroids as Prognostic Biomarkers in Patients Receiving Androgen Deprivation Therapy for Recurrent Prostate Cancer: A Post Hoc Analysis of the PR.7 Trial. <i>Clinical Cancer Research</i> , 2018, 24, 5305-5312.	7.0	13
20	Contemporary outcomes of palliative transurethral resection of the prostate in patients with locally advanced prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 363.e7-363.e11.	1.6	16
21	Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. <i>New England Journal of Medicine</i> , 2017, 376, 1015-1026.	27.0	2,677
22	Metabolic Imaging of Prostate Cancer Reveals Intrapatient Intermetastasis Response Heterogeneity to Systemic Therapy. <i>European Urology Focus</i> , 2017, 3, 639-642.	3.1	15
23	Prospective Evaluation of Nutritional Factors to Predict the Risk of Complications for Patients Undergoing Radical Cystectomy: A Cohort Study. <i>Nutrition and Cancer</i> , 2017, 69, 1196-1204.	2.0	10
24	Preoperative nutritional factors and outcomes after radical cystectomy: A narrative review. <i>Canadian Urological Association Journal</i> , 2017, 11, 419-24.	0.6	5
25	The UGT2B28 Sex-steroid Inactivation Pathway Is a Regulator of Steroidogenesis and Modifies the Risk of Prostate Cancer Progression. <i>European Urology</i> , 2016, 69, 601-609.	1.9	36
26	CSF1 Receptor Targeting in Prostate Cancer Reverses Macrophage-Mediated Resistance to Androgen Blockade Therapy. <i>Cancer Research</i> , 2015, 75, 950-962.	0.9	150
27	FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy. <i>Cancer Imaging</i> , 2015, 15, 2.	2.8	47
28	IL-8 secretion in primary cultures of prostate cells is associated with prostate cancer aggressiveness. <i>Research and Reports in Urology</i> , 2014, 6, 27.	1.0	26
29	Conditional Survival After Radical Cystectomy for Bladder Cancer: Evidence for a Patient Changing Risk Profile over Time. <i>European Urology</i> , 2014, 66, 361-370.	1.9	125
30	Arguments against investing widely in robotic prostatectomy in Canada: a wrong focus on tool box rather than surgical expertise. <i>Canadian Urological Association Journal</i> , 2013, 3, 486.	0.6	5
31	Invasive bladder cancer: time is of the essence. <i>Canadian Urological Association Journal</i> , 2013, 2, 109.	0.6	0
32	Evaluation of the prognostic value of guanylyl cyclase C (GCC) lymph node (LN) classification in patients with stage II colon cancer: A pooled analysis.. <i>Journal of Clinical Oncology</i> , 2012, 30, 443-443.	1.6	0
33	Biomarkers in prostate cancer diagnosis and prognosis: beyond prostate-specific antigen. <i>Current Opinion in Urology</i> , 2009, 19, 243-246.	1.8	40
34	Recent advances in the management of superficial bladder tumors. <i>Canadian Journal of Urology</i> , 2002, 9, 1544-50.	0.0	7
35	Role of radical prostatectomy in high-risk prostate cancer. <i>Canadian Journal of Urology</i> , 2002, 9 Suppl 1, 8-13.	0.0	0
36	Lifetime occupational physical activity and incidental prostate cancer (Canada). <i>Cancer Causes and Control</i> , 2000, 11, 759-764.	1.8	41

#	ARTICLE	IF	CITATIONS
37	Dietary fat and prostate cancer survival. <i>Cancer Causes and Control</i> , 1999, 10, 245-251.	1.8	93
38	Dietary energy and nutrients in relation to preclinical prostate cancer. <i>Nutrition and Cancer</i> , 1997, 29, 120-126.	2.0	67